CME Program from The Doctor's Channel
The intended audience
for this series is cardiologists, endocrinologists, lipidologists, infectious
disease specialists, and other healthcare professionals involved in the
diagnosis and treatment of patients with HIV-associated lipodystrophy.
the conclusion of this series, participants should be able to:
Review the evidence
about the pathogenesis of HIV-associated lipodystrophy, including pathogenic
influences associated with host, disease, and treatment-related factors.
lipodystrophy promptly to improve the overall quality of life in patients with
Use a multidisciplinary
approach to assess the effects of HIV disease and HAART therapeutic regimens on
the metabolic components of lipodystrophy and monitor for metabolic
complications on a regular basis.
Evaluate treatments for
HIV-associated lipodystrophy based on their safety, efficacy, dosage
requirements, and improvement in patients' overall quality of life.
Review the etiology,
pathophysiology, and impact on cardiovascular risk of the complex dyslipidemias
associated with HIV lipodystrophy.
Review the evidence
concerning the efficacy, safety, drug interactions, and appropriate treatment
of the dyslipidemias associated with HIV lipodystrophy to reduce cardiovascular
Clinicians who manage
patients with HIV must be aware of how to screen for, diagnose, and treat
metabolic abnormalities and body shape changes. These video interviews will
review the pathophysiology of lipoatrophy and lipohypertrophy, common body
shape abnormalities observed in patients with HIV. Methods utilized to detect
these body shape changes along with challenges associated with their use will
also be discussed. Finally, management strategies for these metabolic and body
shape abnormalities will be evaluated.
Julian Falutz, MD, FRCPC Director, HIV
Metabolic Clinic Senior Physician, Division of Geriatrics McGill University
Hospital Center Montreal, Quebec